MCID: SRC014
MIFTS: 61

Sarcoma malady

Bone diseases, Cancer diseases categories

Aliases & Classifications for Sarcoma

About this section

Aliases & Descriptions for Sarcoma:

Name: Sarcoma 8 10 44 61
Connective and Soft Tissue Neoplasm 8
 
Tumor of Soft Tissue and Skeleton 8
Sarcoma - Category 61


Classifications:



External Ids:

Disease Ontology8 DOID:1115
SNOMED-CT56 187985009, 93765001
ICD9CM27 171.9, 171

Summaries for Sarcoma

About this section
Disease Ontology:8 A cell type cancer that has material basis in abnormally proliferating cells derived from embryonic mesoderm.

MalaCards based summary: Sarcoma, also known as connective and soft tissue neoplasm, is related to clear cell sarcoma and ewing sarcoma. An important gene associated with Sarcoma is KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), and among its related pathways are Signaling events mediated by focal adhesion kinase and Renal cell carcinoma. The drugs mitoxantrone and mitoxantrone hydrochloride and the compounds ag-1296 and perillyl alcohol have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and liver, and related mouse phenotypes are tumorigenesis and integument.

Wikipedia:64 A sarcoma (from the Greek ???? sarx meaning \"flesh\") is a cancer that arises from transformed cells of... more...

Related Diseases for Sarcoma

About this section

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 799)
idRelated DiseaseScoreTop Affiliating Genes
1clear cell sarcoma32.3BRAF, KIT, EWSR1
2ewing sarcoma32.1EWSR1, FLI1, SS18, KIT
3neuroectodermal tumor31.9FLI1, EWSR1
4peripheral primitive neuroectodermal tumor31.6EWSR1, FLI1
5liposarcoma31.4EWSR1, FLI1
6leukemia31.4FGF4, EWSR1, FES, JUN, FLI1, SRC
7myeloid leukemia31.3FES, JUN, SRC, HRAS, KIT
8melanoma31.1BRAF, FLI1, HRAS, KIT, SSX2, SSX1
9sarcoma, synovial31.1FLI1, SSX1, SS18, SSX2, KIT, SSX4
10breast cancer31.1SRC, HRAS, FGF4
11hemangioma30.9FES, FLI1, FGF4
12glioblastoma30.7KIT, SRC, HRAS, JUN
13seminoma30.7BRAF, SSX2, KIT, FGF4
14ewing's family of tumors30.6EWSR1, FLI1
15colorectal cancer30.4PATZ1, SRC, BRAF, JUN, HRAS
16adenoma30.4FGF4, HRAS, BRAF, SRC
17spitz nevus30.3BRAF, HRAS
18lung cancer30.2HRAS, SRC, JUN, BRAF
19prostate cancer29.8JUN, PATZ1, FLI1, SRC, FGF4
20soft tissue sarcoma11.2
21endometrial stromal sarcoma11.0
22epithelioid sarcoma11.0
23alveolar soft-part sarcoma11.0
24kaposi sarcoma11.0
25myeloid sarcoma10.9
26uterine sarcoma10.9
27dendritic cell sarcoma10.9
28histiocytic sarcoma10.9
29follicular dendritic cell sarcoma10.8
30retroperitoneal sarcoma10.8
31embryonal sarcoma10.8
32spindle cell sarcoma10.8
33endotheliitis10.7
34undifferentiated embryonal sarcoma of the liver10.7
35classic kaposi sarcoma10.7
36rhabdomyosarcoma10.7
37primary effusion lymphoma10.6
38monophasic synovial sarcoma10.6
39interdigitating dendritic cell sarcoma10.6
40langerhans cell sarcoma10.6
41biphasic synovial sarcoma10.6
42extraosseous ewing's sarcoma10.6
43cardiofaciocutaneous syndrome10.5BRAF
44breast sarcoma10.5
45kidney hemangiopericytoma10.5SS18, SSX2
46connective tissue benign neoplasm10.5FLI1, EWSR1
47mast-cell sarcoma10.5
48castleman's disease10.5
49histiocytoma10.5
50fibrous histiocytoma10.5

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to sarcoma

Symptoms for Sarcoma

About this section

Drugs & Therapeutics for Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Doxil13 38 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
FDA Label: Doxil
Malady that Drug Treats: ovarian cancer that is refractory to other first-line therapies
Indications and Usage:13 DOXIL is an anthracycline topoisomerase II inhibitor indicated for:; Ovarian cancer (1.1); After failure of platinum-based chemotherapy.; AIDS-related Kaposi s Sarcoma (1.2); After failure of prior systemic chemotherapy or intolerance to such therapy.; Multiple Myeloma (1.3); In combination with bortezomib in patients who have not previously; received bortezomib and have received at least one prior therapy.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: nucleic acid; synthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of; doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid; synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear; Reference ID: 3733596; 17 ; ; ; ; ; chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and; induction of mutagenesis and chromosomal aberrations.
2
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Taxol13 38 PACLITAXEL Bristol-Myers Squibb Approved August 1997
FDA Label: Taxol
Malady that Drug Treats: Kaposi's Sarcoma
Indications and Usage:13 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of; the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.; Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer; administered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinical; trial, there was an overall favorable effect on disease-free and overall survival in the total population of; patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and; progesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).; Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination; chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy; should have included an anthracycline unless clinically contraindicated.; Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmall; cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation; therapy.; Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi s sarcoma.
DrugBank Targets:11 1. Apoptosis regulator Bcl-2; 2. Tubulin beta-1 chain; 3. Nuclear receptor subfamily 1 group I member 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein 2; 6. Microtubule-associated protein tau
Mechanism of Action:13 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin; dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition; of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and; mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or  bundles of microtubules; throughout the cell cycle and multiple asters of microtubules during mitosis.; Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a; biphasic manner. The initial rapid decline represents distribution to the peripheral compartment and; elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the; peripheral compartment.; Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levels; of 135 and 175 mg/m2; were determined in a Phase 3 randomized study in ovarian cancer patients and are; summarized in the following table:
4
Votrient13 38 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009
FDA Label: Votrient
Malady that Drug Treats: soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:13 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with:; advanced renal cell carcinoma. (1); advanced soft tissue sarcoma who have received prior chemotherapy. (1); Limitation of Use: The efficacy of VOTRIENT for the treatment of patients; with adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has not; been demonstrated.
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3; 4. Platelet-derived growth factor receptor alpha; 5. Platelet-derived growth factor receptor beta; 6. Mast/stem cell growth factor receptor Kit; 7. Fibroblast growth factor receptor 3; 8. Tyrosine-protein kinase ITK/TSK; 9. Fibroblast growth factor 1; 10. SH2B adapter protein 3
Mechanism of Action:13 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor; receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-±; and -², fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2; receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and; transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited; ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-² receptors. In vivo,; pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in; a mouse model, and the growth of some human tumor xenografts in mice.

Drug clinical trials:

Search ClinicalTrials for Sarcoma

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Sarcoma

About this section

Anatomical Context for Sarcoma

About this section

MalaCards organs/tissues related to Sarcoma:

31
Myeloid, Bone, Liver, Kidney, Breast, Endothelial, Lung, Colon, Lymph node, Brain, Uterus, Tongue, Bone marrow, Skin, Prostate, Cervix, Thyroid, T cells, Heart, B cells, Smooth muscle, Monocytes, Ovary, Spleen, Small intestine, Tonsil, Neutrophil, Skeletal muscle, Testes, Spinal cord, Adrenal gland, Pituitary, Testis, Pancreas, Placenta, Appendix, Eye, Salivary gland, B lymphoblasts, Pineal, Thymus, Cerebellum, Retina, Nk cells, Trachea, Pancreatic islet

Animal Models for Sarcoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Sarcoma:

35 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.9BRAF, EWSR1, HRAS, KIT, SRC, FLI1
2MP:00107719.8EWSR1, JUN, BRAF, SRC, FES, HRAS
3MP:00053909.8FGF4, EWSR1, BRAF, JUN, SRC, KIT
4MP:00053799.8EWSR1, JUN, PATZ1, KIT, HRAS, BRAF
5MP:00053809.7KIT, PATZ1, FLI1, JUN, BRAF, SRC
6MP:00053859.7PATZ1, HRAS, KIT, SS18, FES, BRAF
7MP:00028739.7JUN, KIT, FGF4, HRAS, EWSR1, BRAF
8MP:00053889.6JUN, SRC, KIT, BRAF, HRAS, FGF4
9MP:00036319.5BRAF, JUN, FLI1, PATZ1, SRC, SS18
10MP:00053979.5FES, EWSR1, BRAF, SRC, JUN, FLI1
11MP:00053789.5SRC, KIT, SS18, EWSR1, BRAF, JUN
12MP:00107689.3JUN, BRAF, FES, EWSR1, PATZ1, FLI1
13MP:00053879.2PATZ1, JUN, BRAF, FLI1, SRC, KIT

Publications for Sarcoma

About this section

Articles related to Sarcoma:

(show top 50)    (show all 7805)
idTitleAuthorsYear
1
De novo myeloid sarcoma in a 4-month-old infant: a case report and review of the literature. (23095217)
2013
2
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. (24374597)
2013
3
Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein. (24130893)
2013
4
SS18-SSX fusion protein-induced Wnt/I^-catenin signaling is a therapeutic target in synovial sarcoma. (24166495)
2013
5
Monitoring the adequacy of surgical margins after resection of bone and soft-tissue sarcoma. (23370669)
2013
6
Pulmonary artery sarcoma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. (23910141)
2013
7
Regulation of the exopolysaccharide from an anamorph of Cordyceps sinensis on dendritic cell sarcoma (DCS) cell line. (22610670)
2013
8
Inflammatory pseudotumor-like follicular dendritic cell sarcoma of the spleen: a report of six cases with increased IgG4-positive plasma cells. (23714251)
2013
9
Images in vascular medicine. Spindle cell sarcoma of the common femoral vein as a possible differential for deep venous thrombosis on ultrasound. (22951535)
2013
10
Prognostic factors and treatment strategies for adult head and neck soft tissue sarcoma. (22398019)
2012
11
Primitive neuroectodermal tumor/Ewing's sarcoma of the urinary bladder: a case report and its molecular diagnosis. (21063743)
2011
12
High-grade endometrial stromal sarcoma with smooth muscle and skeletal muscle differentiation: report of a case with cytomorphologic and immunocytologic analysis. (20730890)
2011
13
Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. (21277011)
2011
14
Mutational analysis of the latency-associated nuclear antigen DNA-binding domain of Kaposi's sarcoma-associated herpesvirus reveals structural conservation among gammaherpesvirus origin-binding proteins. (20484563)
2010
15
Clinicopathologic features of granulocytic sarcoma: a study of 38 cases]. (20450763)
2010
16
PML down-regulation in soft tissue sarcomas. (20578240)
2010
17
Synovial sarcoma individual chemotherapy directed by collagen gel droplet embedded culture drug sensitivity test: A case report. (22966400)
2010
18
INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics. (19318800)
2009
19
Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. (19107931)
2009
20
Staging of soft tissue sarcoma: what is new? (18685895)
2008
21
An unusual case of febrile neutropenia: acute myeloid leukemia presenting as myeloid sarcoma of the spleen. (18717148)
2008
22
Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). (18760530)
2008
23
Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. (18179547)
2008
24
Evaluation of genetic stability of the SYT gene rearrangement by break-apart FISH in primary and xenotransplanted synovial sarcomas. (17175375)
2007
25
Histiocytic sarcoma of the spleen in flat-coated retrievers with regenerative anaemia and hypoproteinaemia. (16782856)
2006
26
Identification and characterization of the Orf49 protein of Kaposi's sarcoma-associated herpesvirus. (16501115)
2006
27
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. (16585191)
2006
28
Doxorubicin induces cell senescence preferentially over apoptosis in the FU-SY-1 synovial sarcoma cell line. (16705698)
2006
29
Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. (16930603)
2006
30
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. (15652749)
2005
31
Primary endocardial malignant spindle-cell sarcoma in the right atrium of a dog resembling a malignant peripheral nerve sheath tumour. (15893992)
2005
32
Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas. (16082560)
2005
33
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. (15894930)
2005
34
Protection of Ewing's sarcoma family tumor (ESFT) cell line SK-N-MC from betulinic acid induced apoptosis by alpha-DL-tocopherol. (15451550)
2004
35
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. (15355900)
2004
36
Low-grade sarcomas with CD34-positive fibroblasts and low-grade myofibroblastic sarcomas. (15764578)
2004
37
Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis. (12747473)
2003
38
De novo uterine sarcoma with good response to neo-adjuvant chemotherapy. (12801270)
2003
39
APC mutations in synovial sarcoma. (11920741)
2002
40
Immunomodulatory treatment with low-dose interferon-alpha and oral retinoic acid in lymphangioma-like Kaposi's sarcoma. (10769722)
2000
41
Alveolar soft-part sarcoma: further evidence by FISH for the involvement of chromosome band 17q25. (9739024)
1998
42
A third case of a low-grade endometrial stromal sarcoma with a t(7;17)(p14 approximately 21;q11.2 approximately 21). (9309124)
1997
43
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. (8840996)
1996
44
Dramatic response to ifosfamide, mesna and doxorubicin chemotherapy regimen in an adult with clear cell sarcoma of the kidney. (8618315)
1996
45
Inhibition of RNA splicing at the Rous sarcoma virus src 3' splice site is mediated by an interaction between a negative cis element and a chicken embryo fibroblast nuclear factor. (7609076)
1995
46
Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. (8133539)
1994
47
The Fli-1 proto-oncogene, involved in erythroleukemia and Ewing's sarcoma, encodes a transcriptional activator with DNA-binding specificities distinct from other Ets family members. (8502483)
1993
48
Uterine malignancy developing after long term use of IUCD additional report of 2 cases: endometrial stromal sarcoma and leiomyosarcoma. (2597086)
1989
49
Epithelioid sarcoma of penis. (3750610)
1986
50
Alveolar soft-part sarcoma. Report of a case presenting as a sacral bone tumor. (5762710)
1969

Variations for Sarcoma

About this section

Expression for genes affiliated with Sarcoma

About this section
Search GEO for disease gene expression data for Sarcoma.

Pathways for genes affiliated with Sarcoma

About this section

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 89)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.1JUN, SRC, BRAF
210.1JUN, BRAF, HRAS
3
Show member pathways
10.1HRAS, BRAF, JUN
410.1JUN, SRC, HRAS
510.1HRAS, SRC, JUN
610.1JUN, SRC, HRAS
7
Show member pathways
Development Flt3 signaling59
10.1JUN, HRAS, SRC
810.1JUN, HRAS, SRC
9
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades59
10.1SRC, HRAS, JUN
1010.1HRAS, JUN, SRC
11
Show member pathways
Development Activation of ERK by Alpha 1 adrenergic receptors59
10.1SRC, JUN, HRAS
1210.1SRC, JUN, HRAS
13
Show member pathways
10.1SRC, BRAF, HRAS
14
Show member pathways
EPO Receptor Signaling36
EPO signaling pathway36
10.1SRC, FES, HRAS
15
Show member pathways
VEGFR1 specific signals36
10.1FES, HRAS, SRC
16
Show member pathways
10.0BRAF, JUN, KIT, HRAS
17
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
10.0BRAF, JUN, SRC, HRAS
18
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
10.0BRAF, JUN, SRC, HRAS
19
Show member pathways
Immune response BCR pathway59
Fc-epsilon receptor I signaling in mast cells36
10.0JUN, SRC, BRAF, HRAS
20
Show member pathways
10.0BRAF, JUN, SRC, HRAS
21
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
10.0JUN, BRAF, SRC, HRAS
22
Show member pathways
RAC1 signaling pathway36
10.0BRAF, JUN, SRC, HRAS
23
Show member pathways
10.0JUN, BRAF, SRC, HRAS
2410.0HRAS, SRC, JUN, BRAF
25
Show member pathways
10.0BRAF, HRAS, SRC, JUN
26
Show member pathways
Development Beta adrenergic receptors regulation of ERK59
G protein signaling G Protein alpha s signaling cascades59
G protein signaling G Protein beta gamma signaling cascades59
10.0HRAS, SRC, BRAF, JUN
2710.0HRAS, JUN, BRAF, SRC
28
Show member pathways
Development ERBB family signaling59
Development GDNF family signaling59
10.0HRAS, BRAF, JUN, SRC
29
Show member pathways
Signaling events mediated by Stem cell factor receptor (c-Kit)36
10.0HRAS, KIT, SRC, FES
30
Show member pathways
9.9SRC, BRAF, HRAS, FGF4
31
Show member pathways
9.9HRAS, FGF4, SRC, BRAF
32
Show member pathways
Signaling Pathways in Glioblastoma36
9.9BRAF, HRAS, FGF4, SRC
339.9FGF4, BRAF, HRAS, SRC
34
Show member pathways
Signal transduction PTEN pathway59
9.9BRAF, JUN, SRC, KIT, HRAS
35
Show member pathways
Development EDNRB signaling59
Development ACM2 and ACM4 activation of ERK59
Cell adhesion Integrin inside out signaling59
Development G Proteins mediated regulation MARK ERK signaling59
Signal transduction IP3 signaling59
Development Angiotensin signaling via PYK259
Development EPO induced MAPK pathway59
9.9KIT, SRC, JUN, BRAF, HRAS
369.8FGF4, HRAS, KIT, JUN, BRAF
37
Show member pathways
9.8FGF4, KIT, JUN, BRAF, HRAS
38
Show member pathways
9.8KIT, BRAF, SRC, FGF4, HRAS
39
Show member pathways
9.8SRC, BRAF, KIT, FGF4, HRAS
40
Show member pathways
9.8KIT, BRAF, HRAS, FGF4, SRC
41
Show member pathways
9.8BRAF, FGF4, HRAS, KIT, SRC
42
Show member pathways
9.7BRAF, JUN, SRC, HRAS, FGF4, KIT
43
Show member pathways
9.7BRAF, JUN, SRC, KIT, HRAS, FGF4
44
Show member pathways
9.7BRAF, FGF4, JUN, KIT, HRAS, SRC
45
Show member pathways
9.7FGF4, SRC, HRAS, KIT, BRAF, JUN
46
Show member pathways
9.7FES, JUN, SRC, KIT, HRAS, FGF4
47
Show member pathways
9.7FGF4, HRAS, JUN, BRAF, FES, SRC
48
Show member pathways
9.7FGF4, KIT, SSX2IP, SRC, JUN, HRAS
499.6FGF4, KIT, FAU, BRAF, SRC, HRAS
509.6SSX1, EWSR1, FLI1, SSX2, SS18, SSX2B

Compounds for genes affiliated with Sarcoma

About this section

Compounds related to Sarcoma according to GeneCards Suite gene sharing:

(show all 37)
idCompoundScoreTop Affiliating Genes
1ag-12964410.5SRC, KIT
2perillyl alcohol44 2411.5HRAS, JUN
3helenalin4410.5JUN, SRC
4pertussis4410.5HRAS, SRC, JUN
5ebselen4410.5SRC, JUN
6gp 1304410.5HRAS, KIT, SRC
7geldanamycin44 50 60 1113.4SRC, JUN, KIT, BRAF
8ponatinib50 1111.4KIT, SRC
9gf 109203x44 6011.4HRAS, JUN, SRC
10phenylalanine4410.4HRAS, SRC, BRAF, KIT
11paclitaxel44 50 1112.4BRAF, SRC, KIT, HRAS
12phosphotyrosine4410.3FES, SRC, KIT, HRAS
13ly2940024410.3HRAS, SRC, JUN, BRAF
14herbimycin a44 6011.3JUN, SRC, HRAS
15wortmannin4410.3SRC, HRAS, JUN, BRAF
16staurosporin4410.3SRC, JUN
17rapamycin4410.3SRC, JUN, KIT, HRAS, BRAF
18paraffin4410.3BRAF, HRAS, EWSR1, KIT
19pd 98,0594410.3SRC, JUN, HRAS, KIT, BRAF
20phosphoinositide4410.3JUN, HRAS, KIT, BRAF, SRC
21imatinib44 50 1112.3BRAF, SRC, KIT
22matrigel4410.3BRAF, JUN, SRC, FGF4
23regorafenib50 1111.3BRAF, KIT
24glutamine4410.2HRAS, EWSR1, KIT, SS18
25phosphatidylinositol4410.1FES, SRC, KIT, HRAS, JUN, BRAF
26threonine4410.1SRC, HRAS, KIT, JUN, BRAF, FES
27manumycin4410.1SRC, HRAS
28aspartate4410.1HRAS, KIT, SRC, BRAF
29agar4410.1SRC, FGF4, HRAS, JUN, BRAF, FES
30vegf4410.1FGF4, KIT, HRAS, SRC, JUN, BRAF
31estrogen4410.1FGF4, HRAS, SRC, JUN, BRAF, KIT
32arsenite44 2411.1SRC, FAU, JUN
33retinoic acid44 2411.0EWSR1, FES, BRAF, JUN, KIT, FGF4
34oligonucleotide449.9PATZ1, KIT, BRAF, SSX2, FLI1, JUN
35serine449.9FLI1, SRC, KIT, JUN, BRAF, FES
36valine449.8KIT, BRAF, HRAS
37tyrosine449.7FGF4, EWSR1, FES, BRAF, HRAS, KIT

GO Terms for genes affiliated with Sarcoma

About this section

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytosolGO:00058299.4BRAF, JUN, FAU, ASPSCR1, SRC, HRAS
2nucleusGO:00056348.2FGF4, EWSR1, BRAF, FLI1, PATZ1, ASPSCR1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1peptidyl-tyrosine phosphorylationGO:001810810.3KIT, SRC, FES
2positive regulation of actin cytoskeleton reorganizationGO:0200025110.3HRAS, FES
3organ morphogenesisGO:000988710.2HRAS, BRAF, FLI1
4T cell differentiationGO:003021710.2PATZ1, KIT
5positive regulation of ERK1 and ERK2 cascadeGO:007037410.2SRC, FGF4, BRAF, HRAS
6Fc-epsilon receptor signaling pathwayGO:003809510.2FGF4, KIT, JUN, HRAS
7epidermal growth factor receptor signaling pathwayGO:000717310.2SRC, KIT, FGF4, HRAS
8regulation of cell motilityGO:0200014510.2FES, SSX2IP
9fibroblast growth factor receptor signaling pathwayGO:000854310.1FGF4, BRAF, KIT, HRAS, SRC
10neurotrophin TRK receptor signaling pathwayGO:004801110.1HRAS, BRAF, SRC, KIT, FGF4
11innate immune responseGO:004508710.0FGF4, HRAS, KIT, SRC, JUN
12negative regulation of neuron apoptotic processGO:004352410.0HRAS, BRAF, JUN
13protein autophosphorylationGO:00467779.8FES, KIT, SRC
14regulation of transcription, DNA-templatedGO:00063559.7SSX6, SSX2B, EWSR1, PATZ1, SSX1, SSX4B
15transcription, DNA-templatedGO:00063519.7PATZ1, SS18, SSX2B, SSX6, SSX4B, SSX1

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein tyrosine kinase activityGO:00047139.8FES, SRC, KIT
2nucleic acid bindingGO:00036769.8SSX2B, SSX6, SSX4B, SSX1
3protein bindingGO:00055159.1FES, BRAF, JUN, ASPSCR1, SRC, SSX2IP

Sources for Sarcoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet